porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2011237-39porozendo-4165Research ArticleСтатьиArticlesЗОЛЕДРОНОВАЯ КИСЛОТА В ПРОФИЛАКТИКЕ ПОТЕРИ КОСТНОЙ ТКАНИ У жЕНЩИН ПОСТМЕНОПАУЗАЛЬНОГО ВОЗРАСТА С ОСТЕОПЕНИЕЙZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEYMcclungMichael

MD

-MillerPaul

MD

-RecknorChris

MD

-MesenbrinkPeter

PHD

-Bucci-RechtwegChristina

MD

-BenhamouClaude-Laurent

MD

-201115082011142№2 (2011)3739Copyright © Mcclung M., Miller P., Recknor C., Mesenbrink P., Bucci-Rechtweg C., Benhamou C., 20112011Mcclung M., Miller P., Recknor C., Mesenbrink P., Bucci-Rechtweg C., Benhamou C.Mcclung M., Miller P., Recknor C., Mesenbrink P., Bucci-Rechtweg C., Benhamou C.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4165

Профилактика остеопоротических переломов, особенно бедренной кости и позвонков, - это важная проблема здравоохранения. Подобные переломы сопровождаются повышенным риском осложнений и смерти, поэтому эффективная стратегия их профилактики может оказать значительное влияние на заболеваемость и несколько меньшее, но существенное влияние на смертность пожилых людей. 1-3 Хотя у женщин с остепенией риск развития переломов ниже, чем у женщин того же возраста с остеопорозом, тем не менее, при отсутствии лечения у них высока вероятность развития остеопороза. Более того, большинство переломов регистрируют у пациенток с остеопенией. 4 В последних рекомендациях женщинам постменопаузального возраста с остеопенией и со средним или высоким риском переломов (оценивают с помощью валидированных методов, таких как FRAX) предлагается назначать лекарственные средства, предназначенные для лечения остеопороза. 5 Пероральные бисфосфонаты предупреждают потерю костной ткани после наступления менопаузы у женщин более молодого и старшего возраста 6-8 Однако в клинической практике многие пациентки плохо выполняют рекомендации врача и принимают пероральные бисфосфонаты в течение не более нескольких месяцев. 9 В связи с этим важное значение имеет применение эффективного препарата, обеспечивающего высокую приверженность пациенток. В клинических исследованиях доказано, что ежегодные инфузии золедроновой кислоты в дозе 5 мг в течение 3 лет снижают риск переломов позвонков, бедренной кости и внепозвоночных переломов и увеличивают МПК поясничных позвонков и бедренной кости у женщин с постменопаузальным остеопорозом. 10 Кроме того, препарат снижал риск повторных клинически явных переломов у мужчин и женщин, недавно перенесших остеопоротический перелом бедренной кости. 11 Целью данного исследования было изучение эффективности и переносимости внутривенных инфузий золедроновой кислоты в дозе 5 мг у женщин постменопаузального возраста с остеопенией. В 2-летнем исследовании изучали эффективность двух и одной инфузии препарата, чтобы оценить возможность сокращения числа инфузий для профилактики потери костной ткани.

ReferencesMiller R.G. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture. Geriatrics 2006;61: 24-30.Miller R.G. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture. Geriatrics 2006;61: 24-30.Brown J.P., Josse R.G., 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [published errata appear in CMAJ 2003; 168: 400, CMAJ 2003; 168: 676, and CMAJ 2003; 168: 544]. CMAJ. 2002;167 (10 Suppl): S1-34.Brown J.P., Josse R.G., 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [published errata appear in CMAJ 2003; 168: 400, CMAJ 2003; 168: 676, and CMAJ 2003; 168: 544]. CMAJ. 2002;167 (10 Suppl): S1-34.Siris E.S., Miller P.D., Barrett-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-22.Siris E.S., Miller P.D., Barrett-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-22.National Osteoporosis Foundation 2008. Available at: http://www.nof.org/ professionals/NOF±Clinicians±Guide.pdf. Retrieved July 11, 2009.National Osteoporosis Foundation 2008. Available at: http://www.nof.org/ professionals/NOF±Clinicians±Guide.pdf. Retrieved July 11, 2009.McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128: 253-61.McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128: 253-61.McClung M., Siris E., Cummings S., Bolognese M., Ettinger M., Moffett A., et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13: 377-86.McClung M., Siris E., Cummings S., Bolognese M., Ettinger M., Moffett A., et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13: 377-86.McClung M., Recker R., Miller P., Fiske D., Minkoff J., Kriegman A., et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007; 41: 122-8.McClung M., Recker R., Miller P., Fiske D., Minkoff J., Kriegman A., et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007; 41: 122-8.Boccuzzi S.J., Folz S.H., Omar M.A., Kahler K.H. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 2005; 16 (Suppl 4): S35-6.Boccuzzi S.J., Folz S.H., Omar M.A., Kahler K.H. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 2005; 16 (Suppl 4): S35-6.Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.Lyles K.W., Colo'n-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809Lyles K.W., Colo'n-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61.Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61.Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-94.Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-94.Reginster J.Y., Collette J., Neuprez A., Zegels B., Deroisy R., Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008; 42: 832-6.Reginster J.Y., Collette J., Neuprez A., Zegels B., Deroisy R., Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008; 42: 832-6.Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with microcomputed tomography. Bone 2006; 39: 345-52Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with microcomputed tomography. Bone 2006; 39: 345-52Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., Delmas P.D. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005; 20: 1813-9.Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., Delmas P.D. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005; 20: 1813-9.Wainwright S.A., Marshall L.M., Ensrud K.E., Cauley J.A., Black D.M., Hillier T.A., et al. Hip fracture in women without osteoporosis J Clin Endocrinol Metab 2005; 90: 2787-93Wainwright S.A., Marshall L.M., Ensrud K.E., Cauley J.A., Black D.M., Hillier T.A., et al. Hip fracture in women without osteoporosis J Clin Endocrinol Metab 2005; 90: 2787-93Menopause and osteoporosis update 2009. http://www.sogc.org/guidelines/ documents/Menopause±JOGC-Jan±09.pdf. Retrieved July 11, 2009.Menopause and osteoporosis update 2009. http://www.sogc.org/guidelines/ documents/Menopause±JOGC-Jan±09.pdf. Retrieved July 11, 2009.Drake W.M., Kendler D.L., Rosen C.J., Orwoll E.S. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88: 5759-65.Drake W.M., Kendler D.L., Rosen C.J., Orwoll E.S. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88: 5759-65.Lenora J., Ivaska K.K., Obrant K.J., Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18: 1297-305.Lenora J., Ivaska K.K., Obrant K.J., Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18: 1297-305.Reginster J.Y., Deroisy R., Collete J., Albert A., Zegels B. Prediction of bone loss rate in healthy postmenopausal women. Calcif Tissue Int 1997;60: 261-4.Reginster J.Y., Deroisy R., Collete J., Albert A., Zegels B. Prediction of bone loss rate in healthy postmenopausal women. Calcif Tissue Int 1997;60: 261-4.Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res 1999; 14: 1614-21.Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res 1999; 14: 1614-21.Rogers A., Hannon R.A., Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000; 15: 1398-404.Rogers A., Hannon R.A., Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000; 15: 1398-404.Garnero P., Munoz F., Sornay-Rendu E., Delmas P.D. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007; 40: 716-22.Garnero P., Munoz F., Sornay-Rendu E., Delmas P.D. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007; 40: 716-22.McClung M.R. Osteopenia: to treat or not to treat? Ann Intern Med 2005; 142: 796-7.McClung M.R. Osteopenia: to treat or not to treat? Ann Intern Med 2005; 142: 796-7.Watts N.B. What is osteopenia, and what should be done about it? Cleve Clin J Med 2006; 73: 29Watts N.B. What is osteopenia, and what should be done about it? Cleve Clin J Med 2006; 73: 29Khosla S., Melton III L.J. Clinical practice. Osteopenia. N Engl J Med 2007; 356: 2293-300.Khosla S., Melton III L.J. Clinical practice. Osteopenia. N Engl J Med 2007; 356: 2293-300.Schousboe J.T., Nyman J.A., Kane R.L., Ensrud K.E. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142: 734-41.Schousboe J.T., Nyman J.A., Kane R.L., Ensrud K.E. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142: 734-41.Meadows E.S., Klein R., Rousculp M.D., Smolen L., Ohsfeldt R.L., Johnston J.A. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health 2007; 7: 6Meadows E.S., Klein R., Rousculp M.D., Smolen L., Ohsfeldt R.L., Johnston J.A. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health 2007; 7: 6Chen Y.T., Miller P.D., Barrett-Connor E., Weiss T.W., Sajjan S.G., Siris E.S. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007; 18: 1287-96.Chen Y.T., Miller P.D., Barrett-Connor E., Weiss T.W., Sajjan S.G., Siris E.S. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007; 18: 1287-96.Simon J.A. Does osteopenia warrant treatment? Menopause 2005; 12: 639-48.Simon J.A. Does osteopenia warrant treatment? Menopause 2005; 12: 639-48.Wasnich R.D., Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6.Wasnich R.D., Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6.

The authors declare that there are no conflicts of interest present.